Hypoxia-Preconditioned hBMSCs Enhance Mitochondrial Transfer via Gap Junctions in Liver Ischemia-Reperfusion Injury

Study Background and Research Question

Liver transplantation remains limited by ischemia-reperfusion injury (IRI), a process that impairs early graft function due to mitochondrial dysfunction, calcium overload, and oxidative stress during the reperfusion phase. Current management strategies for hepatic IRI are largely symptomatic, with an unmet need for targeted approaches to protect mitochondrial function and improve transplant outcomes. Human bone marrow-derived mesenchymal stem cells (hBMSCs) have shown potential in ameliorating IRI, but the mechanisms underpinning their protective effects, particularly with hypoxia-preconditioning, are not fully understood.

Luo et al. (2025) address the central question: can hypoxia-preconditioned hBMSCs (hypo-hBMSCs) confer superior protection against hepatic IRI by enhancing mitochondrial function and transfer to hepatocytes, and what role do gap junctions—especially connexin 43 (Cx43)—play in this process (Luo et al., 2025)?

Key Innovation from the Reference Study

This study provides the first mechanistic evidence that hypoxia-preconditioning not only improves the quality of hBMSC mitochondria via induced mitophagy but also increases the efficiency of mitochondrial transfer to hepatocytes through gap junctions. Notably, the work demonstrates that upregulated expression of Cx43 and Cx32 in hypo-hBMSCs leads to the formation of homotypic gap junctions with recipient hepatocytes, directly facilitating high-quality mitochondrial transfer and hepatoprotection during IRI (Luo et al., 2025).

Methods and Experimental Design Insights

The researchers employed a multi-tiered approach combining in vitro and in vivo assays:

• Hypoxia preconditioning: hBMSCs were cultured under hypoxic conditions to induce preconditioning, then assessed for mitochondrial quality by measuring membrane potential, reactive oxygen species (ROS), and mitophagy markers.
• In vivo hepatic IRI model: Portal vein injection of hBMSCs or hypo-hBMSCs was performed in rat liver grafts undergoing ischemia-reperfusion, with subsequent measurement of liver injury markers and mitochondrial transfer.
• Gap junction modulation: The function of gap junctions was selectively enhanced (with retinoic acid, RA) or inhibited (with Gap26 connexin 43 mimetic peptide) both in vitro and in vivo. This allowed direct assessment of gap junction dependence for mitochondrial transfer.
• Bioinformatics and molecular techniques: Upregulation of Cx43 and Cx32 in hypo-hBMSCs was confirmed via transcriptomic analysis, siRNA knockdown, overexpression, and co-immunoprecipitation to verify gap junction composition and formation.

Core Findings and Why They Matter

1. Hypoxia preconditioning improves mitochondrial quality in hBMSCs. Preconditioned cells exhibited reduced superoxide accumulation and increased mitochondrial membrane potential, attributable to enhanced mitophagy. This step is crucial for generating donor cells with optimal organelle fitness (Luo et al., 2025).

2. Hypo-hBMSCs alleviate liver IRI more effectively than non-preconditioned hBMSCs. In a rat model, the administration of hypo-hBMSCs led to significant reductions in serum transaminases and histological liver injury, corresponding with greater mitochondrial transfer to hepatocytes.

3. Gap junctions—specifically Cx43 and Cx32—are essential for mitochondrial transfer. Modulation of gap junction activity with RA (enhancer) increased mitochondrial transfer, while the application of Gap26 (connexin 43 mimetic peptide, a selective gap junction blocker) significantly reduced transfer and hepatoprotection. This direct evidence links mitochondrial delivery to functional gap junction communication (Luo et al., 2025).

4. Only homotypic not heterotypic GJs are formed between hypo-hBMSCs and hepatocytes. Elevated Cx43 and Cx32 in donor cells form homotypic Cx43-GJs and Cx32-GJs with hepatocytes, with no evidence for mixed Cx43-Cx32 gap junctions. This specificity may inform future targeting strategies for mitochondrial transfer.

These findings are particularly important for the field of calcium signaling modulation and ATP release inhibition, as the blockade of connexin 43 hemichannels with Gap26 has previously been shown to modulate these pathways in both vascular smooth muscle and neural tissues (internal review).

Comparison with Existing Internal Articles

Internal reviews have long established Gap26 as a robust tool to selectively inhibit connexin 43-mediated gap junction and hemichannel signaling in research settings spanning vascular smooth muscle research, neurobiology, and disease modeling (internal article; internal review). Luo et al. (2025) extend this paradigm by demonstrating that Gap26 can directly disrupt the mitochondrial transfer process between hBMSCs and hepatocytes in an in vivo model of liver IRI, not just block ion or ATP flux. This mechanistic bridge highlights how gap junction modulation—beyond electrical or metabolic coupling—can regulate intercellular organelle trafficking.

Furthermore, while earlier resources have focused on neuroprotection research and modeled calcium wave propagation, the reference study advances the translational relevance of gap junction blockers in tissue repair and transplantation biology. This aligns with recent commentary that positions Gap26 as a preferred tool for dissecting both conventional and unconventional roles of gap junctions in cell therapy contexts (internal translational review).

Limitations and Transferability

Despite the compelling in vivo and in vitro evidence, several limitations exist:

• The study is conducted in rodent models, and the transferability to human clinical transplantation remains to be validated.
• The specificity of mitochondrial transfer via gap junctions—versus other mechanisms such as tunneling nanotubes or vesicular trafficking—could not be fully excluded and may warrant further investigation.
• Only homotypic gap junctions (Cx43-GJs and Cx32-GJs) were functionally implicated; whether other connexins or post-translational modifications alter transfer efficiency in diverse tissues remains unknown.

Nonetheless, the work provides a robust platform for exploring targeted peptide inhibitor of gap junctions strategies in ex vivo organ protection, with potential extension to other ischemic injury models. As discussed in the internal literature, the maturity of this approach in preclinical settings is high, but clinical translation will require additional pharmacodynamic and safety studies.

Protocol Parameters

• cell culture, Gap26 peptide incubation | 0.25 mg/mL, 30 min | in vitro hBMSC–hepatocyte co-culture | effective GJ inhibition for mitochondrial transfer assays | product_spec
• animal model, Gap26 administration | 300 µM, 45 min | in vivo hepatic IRI model | disrupts GJ-mediated organelle transfer and ATP signaling | product_spec
• Gap26 solubility | >155.1 mg/mL in water (ultrasonic); >77.55 mg/mL in DMSO (warmed) | peptide stock preparation | ensures reproducible dosing in preclinical workflows | product_spec
• custom titration for novel tissue models | 10–500 µM, 10–60 min | exploratory gap junction studies | optimize for cell type and endpoint sensitivity | workflow_recommendation

Research Support Resources

For researchers seeking to reproduce or extend these findings, Gap26 (Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg) Connexin 43 Mimetic Peptide (SKU A1044) from APExBIO is validated for selective inhibition of Cx43-mediated gap junctions and hemichannels, supporting advanced workflows in mitochondrial transfer, calcium signaling, and ATP release assays (workflow reference). Appropriate handling, storage, and protocol optimization are essential for reproducible results in both in vitro and in vivo models. This reagent is intended strictly for research use and not for clinical or diagnostic applications.